|
1
|
Varma MV: Role of intestinal transporters
and metabolism in the oral absorption of drug and prodrugs. Curr
Drug Metab. 11:7152010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katsura T and Inui K: Intestinal
absorption of drugs mediated by drug transporters: mechanisms and
regulation. Drug Metab Pharmacokinet. 18:1–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugiura T, Kato Y and Tsuji A: Role of SLC
xenobiotic transporters and their regulatory mechanisms PDZ
proteins in drug delivery and disposition. J Control Release.
116:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rankin KS, Starkey M, Lunec J, et al: Of
dogs and men: comparative biology as a tool for the discovery of
novel biomarkers and drug development targets in osteosarcoma.
Pediatr Blood Cancer. 58:327–333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang W, Jiang J, Ballard CE and Wang B:
Prodrug approaches to the improved delivery of peptide drugs. Curr
Pharm Des. 5:265–287. 1999.PubMed/NCBI
|
|
6
|
Shin HC, Kim HR, Cho HJ, et al:
Comparative gene expression of intestinal metabolizing enzymes.
Biopharm Drug Dispos. 30:411–421. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang H, Tong W, Perkins R, et al:
Bioinformatics approaches for cross-species liver cancer analysis
based on microarray gene expression profiling. BMC Bioinformatics.
6(Suppl 2): S62005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Landowski CP, Sun D, Foster DR, et al:
Gene expression in the human intestine and correlation with oral
valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther.
306:778–786. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takara K, Ohnishi N, Horibe S and Yokayama
T: Expression profiles of drug-metabolizing enzyme CYP3A and drug
efflux transporter multidrug resistance 1 subfamily mRNAS in small
intestine. Drug Metab Dispos. 31:1235–1239. 2003. View Article : Google Scholar
|
|
10
|
Rushmore TH and Kong AN: Pharmacogenomics,
regulation and signaling pathways of phase I and II drug
metabolizing enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mizuno N, Niwa T, Yotsumoto Y and Sugiyama
Y: Impact of drug transporter studies on drug discovery and
development. Pharmacol Rev. 55:425–461. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beaumont K: The importance of gut wall
metabolism in determining drug bioavailability. Drug
Bioavailability/Estimation of Solubility, Permeability and
Absorption. van de Waterbeemd H, Lennernas H and Artursson P:
Wiley-VCH; Weinheim: pp. 311–328. 2003
|
|
13
|
Tsuji A: Transporter-mediated drug
interactions. Drug Metab Pharmacokinet. 17:253–274. 2002.
View Article : Google Scholar
|
|
14
|
Mizuma T, Ohta K and Awazu S: The
beta-anomeric and glucose preferences of glucose transport carrier
for intestinal active absorption of monosaccharide conjugates.
Biochim Biophys Acta. 1200:117–122. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao FQ and Keating AF: Expression and
regulation of glucose transporters in the bovine mammary gland. J
Dairy Sci. 90(Suppl 1): E76–E86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stelmańskan E: The important role of GLUT2
in intestinal sugar transport and absorption. Postepy Biochem.
55:385–387. 2009.(In Polish).
|
|
17
|
Phay JE, Hussain HB and Moley JF: Cloning
and expression analysis of a novel member of the facilitative
glucose transporter family, SLC2A9 (GLUT9). Genomics. 66:217–220.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tate BJ, Witort E, McKenzie IF and Hogarth
PM: Expression of the high responder/non-responder human Fc gamma
RII. Analysis by PCR and transfection into FcR-COS cells. Immunol
Cell Biol. 70(Pt 2): 79–87. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wells RG and Hediger MA: Cloning of a rat
kidney cDNA that stimulates dibasic and neutral amino acid
transport and has sequence similarity to glucosidases. Proc Natl
Acad Sci USA. 89:5596–5600. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seal CJ and Parker DS: Isolation and
characterization of circulating low molecular weight peptides in
steer, sheep and rat portal and peripheral blood. Comp Biochem
Physiol B. 99:679–685. 1991.PubMed/NCBI
|
|
21
|
Lee VH, Chu C, Mahlin ED, et al:
Biopharmaceutics of transmucosal peptide and protein drug
administration: role of transport mechanisms with a focus on the
involvement of PepT1. J Control Release. 62:129–140. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim HR, Park SW, Cho HJ, et al:
Comparative gene expression profiles of intestinal transporters in
mice, rats and humans. Pharmacol Res. 56:224–236. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abumrad N, Harmon C and Ibrahimi A:
Membrane transport of long-chain fatty acids: evidence for a
facilitated process. J Lipid Res. 39:2309–2318. 1998.PubMed/NCBI
|
|
24
|
Thumser AE and Storch J: Liver and
intestinal fatty acid-binding proteins obtain fatty acids from
phospholipid membranes by different mechanisms. J Lipid Res.
41:647–656. 2000.PubMed/NCBI
|
|
25
|
Schaffer JE and Lodish HF: Expression
cloning and characterization of a novel adipocyte long chain fatty
acid transport protein. Cell. 79:427–436. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Traut TW: Physiological concentrations of
purines and pyrimidines. Mol Cell Biochem. 140:1–22. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
el Kouni MH: Trends in the design of
nucleoside analogues as anti-HIV drugs. Curr Pharm Des. 8:581–593.
2002.PubMed/NCBI
|
|
28
|
Damaraju VL, Damaraju S, Young JD, et al:
Nucleoside anti-cancer drugs: the role of nucleoside transporters
in resistance to cancer chemotherapy. Oncogene. 22:7524–7536. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sandusky GE, Mintze KS, Pratt SE and
Dantzig AH: Expression of multidrug resistance-associated protein 2
(MRP2) in normal human tissues and carcinomas using tissue
microarrays. Histopathology. 41:65–74. 2002. View Article : Google Scholar
|
|
30
|
Tang F and Borchardt RT: Characterization
of the efflux transporter(s) responsible for restricting intestinal
mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the
opioid peptide DADLE. Pharm Res. 19:780–786. 2002. View Article : Google Scholar
|
|
31
|
Miyazaki H, Sekine T and Endou H: The
multispecific organic anion transporter family: properties and
pharmacological significance. Trends Pharmacol Sci. 25:654–662.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bahn A, Hagos Y, Reuter S, et al:
Identification of a new urate and high affinity nicotinate
transporter, hOAT10 (SLC22A13). J Biol Chem. 283:16332–16341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
